Seminar: Next Directions in Dystrophinopathy Therapies

TBA

SPEAKER

Kevin M. Flanigan, MD, is the Robert F. and Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital, and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine. Certified by the American Board of Psychiatry and Neurology in both Neurology and Neuromuscular Medicine, Dr. Flanigan is director of the Jerry R. Mendell Center for Gene Therapy in the Abigail Wexner Research Institute at Nationwide Children’s Hospital and a leading expert in neuromuscular disorders. He also leads the world-class Neuromuscular Disorders program at Nationwide Children's, which provides coordinated care with pediatric experts from more than a dozen specialties.

Dr. Flanigan earned his medical degree from Rush Medical College and completed his internship at the University of Michigan Health System before completing his Neurology residency and fellowship in Neuromuscular Disorders at the Johns Hopkins Hospital, and an additional post-doctoral laboratory fellowship in Human Molecular Biology and Genetics at the University of Utah.

His primary research interest is in the genetic and molecular characterization of inherited neuromuscular diseases, and the development of therapies directed toward these diseases. A major focus of his laboratory concerns genotype/phenotype correlation in the dystrophinopathies, with the intention of increasing our understanding of the pathogenesis in this disease and translating this understanding into improved therapies. An experienced clinical trialist, he has sponsored three investigator-initiated IND applications for first-in-human gene therapies for Duchenne muscular dystrophy and Sanfilippo syndrome. He is a member of the Executive Board of the World Muscle Society, and a past chair of TREAT-NMD, the international neuromuscular disease consortium.